
TMO Stock Forecast & Price Target
TMO Analyst Ratings
Bulls say
Thermo Fisher Scientific is projected to experience revenue growth across its segments, with lab products and services anticipated to grow at a 5.4% compound annual rate in the next three years, although this marks a slowdown from the 16.9% growth rate seen from 2019 to 2024. The company is also expected to gain market share in the Contract Research Organization (CRO) sector, buoyed by favorable trends in biopharma clinical trial outsourcing, which indicates a notable increase in demand for outsourced services. Additionally, the forecast for adjusted earnings per share (EPS) suggests a robust increase at an 8.5% compound annual rate over the next four years, reinforcing a positive financial outlook for the company.
Bears say
Thermo Fisher Scientific has experienced a significant decline in its adjusted EBIT margin, dropping approximately 830 basis points to 22.6% from 2021 to 2024, primarily driven by a corresponding 940-basis-point decrease in adjusted gross margin. The company's adjusted gross margin fell to 42.2%, marking a reduction of about 420 basis points compared to the 46.4% gross margin recorded in 2019. Furthermore, despite a noted improvement in biotech customer sentiment, funding levels in 2025 have started sluggishly, with a nearly 45% year-over-year decline in raised capital in the first half of the year.
This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.
TMO Analyst Forecast & Price Prediction
Start investing in TMO
Order type
Buy in
Order amount
Est. shares
0 shares